Loading…

Photonic control of image-guided ferroptosis cancer nanomedicine

[Display omitted] •Photonic ferroptosis cancer nanomedicine with photodynamic therapy/photothermal therapy/immunotherapy.•Luminescence/Photoacoustic/Fluorescence/Computed Tomography/Ultrasound image-guided photonic ferroptosis cancer nanomedicine.•Photonic control of the coordination ferroptosis nan...

Full description

Saved in:
Bibliographic Details
Published in:Coordination chemistry reviews 2024-02, Vol.500, p.215532, Article 215532
Main Authors: Ko, Min Jun, Yoo, Woojung, Min, Sunhong, Zhang, Yu Shrike, Joo, Jinmyoung, Kang, Heemin, Kim, Dong-Hyun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Photonic ferroptosis cancer nanomedicine with photodynamic therapy/photothermal therapy/immunotherapy.•Luminescence/Photoacoustic/Fluorescence/Computed Tomography/Ultrasound image-guided photonic ferroptosis cancer nanomedicine.•Photonic control of the coordination ferroptosis nanomaterials for the image-guided local ferroptosis cancer therapy.•Hybrid photonic nanomaterials for combinational ferroptosis cancer nanomedicine. Photonic nanomaterials, characterized by their remarkable photonic tunability, empower a diverse range of applications, including cutting-edge advances in cancer nanomedicine. Recently, ferroptosis has emerged as an promising alternative strategy for effectively killing cancer cells with minimizing therapeutic resistance. Novel design of photonic nanomaterials that can integrate photoresponsive-ferroptosis inducers, -diagnostic imaging, and -synergistic components provide significant benefits to effectively trigger local ferroptosis. This review provides a comprehensive overview of recent advancements in photonic nanomaterials for image-guided ferroptosis cancer nanomedicine, offering insights into their strengths, constraints, and their potential as a future paradigm in cancer treatment.
ISSN:0010-8545
1873-3840
DOI:10.1016/j.ccr.2023.215532